(Q35664623)

9 August 2017

1 reference

title

HMG-CoA reductase inhibitor use in the aged. A review of clinical experience (English)

1 reference

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1493355

2 October 2022

author name string

C. J. Lintott

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1493355

2 October 2022

R. S. Scott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1493355

2 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1493355

2 October 2022

publication date

1 November 1992

1 reference

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

518-529

1 reference

9 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199202060-00007

9 August 2017

0 references

cites work

Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias

1 reference

12 December 2020

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

1 reference

12 December 2020

Lovastatin. Warfarin interaction

1 reference

12 December 2020

ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium

1 reference

12 December 2020

Effect of lovastatin on hemorheology in type II hyperlipoproteinemia

1 reference

12 December 2020

Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels

1 reference

12 December 2020

Hypercholesterolaemia in aged patients. To treat or not to treat?

1 reference

12 December 2020

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

1 reference

12 December 2020

HMG-CoA reductase inhibitors for hypercholesterolemia

1 reference

12 December 2020

Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I

1 reference

12 December 2020

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1 reference

12 December 2020

A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV

1 reference

12 December 2020

Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)

1 reference

12 December 2020

Clinical experience with simvastatin compared with cholestyramine

1 reference

12 December 2020

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease

1 reference

12 December 2020

Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin.

1 reference

12 December 2020

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study

1 reference

12 December 2020

Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics

1 reference

12 December 2020

Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia

1 reference

12 December 2020

Efficacy and tolerability of lovastatin in a six-month study: analysis by gender, age and hypertensive status.

1 reference

12 December 2020

Lovastatin, pravastatin, and serum lipoprotein(a)

1 reference

12 December 2020

Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia.

1 reference

12 December 2020

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

1 reference

12 December 2020

Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study

1 reference

12 December 2020

Simvastatin: the clinical profile

1 reference

12 December 2020

A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.

1 reference

12 December 2020

Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system

1 reference

12 December 2020

[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]

1 reference

12 December 2020

Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?

1 reference

12 December 2020

Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I

1 reference

12 December 2020

Epidemiologic considerations in cardiovascular diseases in the elderly: international comparisons and trends

1 reference

12 December 2020

Cardiovascular disease in the elderly: current considerations

1 reference

12 December 2020

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

1 reference

12 December 2020

Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia

1 reference

12 December 2020

Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II

1 reference

12 December 2020

Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation

1 reference

12 December 2020

Unchanged serum lipoprotein (a) concentrations with lovastatin

1 reference

12 December 2020

Prevention of restenosis by lovastatin after successful coronary angioplasty

1 reference

12 December 2020

Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia

1 reference

12 December 2020

Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension

1 reference

12 December 2020

Influence of lovastatin on concentrations and composition of lipoprotein subfractions

1 reference

12 December 2020

Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia

1 reference

12 December 2020

Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles

1 reference

12 December 2020

Simvastatin: a review of its pharmacology and clinical use.

1 reference

12 December 2020

The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.

1 reference

12 December 2020

Health promotion and the compression of morbidity

1 reference

12 December 2020

Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment

1 reference

12 December 2020

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

1 reference

12 December 2020

Simvastatin (MK 733): an effective treatment for hypercholesterolemia

1 reference

12 December 2020

Clinical considerations regarding treatment of hypercholesterolemia in the elderly

1 reference

12 December 2020

Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

12 December 2020

Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II)

1 reference

12 December 2020

Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

1 reference

12 December 2020

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

1 reference

12 December 2020

Simvastatin and side effects

1 reference

12 December 2020

Effectiveness of low-dose lovastatin in lowering serum cholesterol. Experience with 56 patients

1 reference

12 December 2020

Lovastatin therapy in heterozygous familial hypercholesterolaemic patients: effect on blood rheology and fibrinogen levels

1 reference

12 December 2020

Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.

1 reference

12 December 2020

Comparison of different HMG-CoA reductase inhibitors

1 reference

12 December 2020

Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil

1 reference

12 December 2020

Fasting serum cholesterol and triglycerides in a ten-year prospective study in old age.

1 reference

12 December 2020

HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels

1 reference

12 December 2020

Hypercholesterolemia in elderly persons: resolving the treatment dilemma

1 reference

12 December 2020

Raised serum lipoprotein during treatment with lovastatin

1 reference

12 December 2020

Long-term clinical tolerance of lovastatin and simvastatin

1 reference

12 December 2020

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia

1 reference

12 December 2020

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

1 reference

12 December 2020

Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

1 reference

12 December 2020

Prescribed use of cholesterol-lowering drugs in the United States, 1978 through 1988.

1 reference

12 December 2020

Combination drug therapy for familial combined hyperlipidemia

1 reference

12 December 2020

High blood cholesterol in elderly men and the excess risk for coronary heart disease

1 reference

12 December 2020

Cholesterol and coronary heart disease. The importance of patient-specific attributable risk

1 reference

12 December 2020

Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Hospital care for elderly patients with diseases of the circulatory system. A comparison of hospital use in the United States and Canada

1 reference

12 December 2020

10.2165/00002512-199202060-00007

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference